EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients.
EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients.
复制标题
DOI:
10.21037/tcr.2018.10.06
复制
发表时间:
2019-01
影响因子:
0.9
通讯作者:
Rosell R
中科院分区:
文献类型:
--
作者:
Karachaliou N;Fernandez-Bruno M;Bracht JWP;Rosell R
Identification of epidermal growth factor receptor (EGFR) as a molecular target has radically changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard chemotherapy to personalized, targeted therapy. First-, second- and third-generation EGFR tyrosine kinase inhibitors (TKIs) are now available for the treatment of EGFR-mutant NSCLC patients. This review will focus on the clinical development of first- and second-generation EGFR TKIs. We will emphasize on essential points like the head-to-head comparison among EGFR TKIs, their activity on brain metastases, mechanisms of resistance, as well as their combination with anti-angiogenic compounds, other targeted therapies, or immunotherapy. The efficacy of first- and second-generation EGFR TKIs in early-stage EGFR-mutant NSCLC will be also finally reviewed.
登录
查看更多内容
影响因子:
30.8
作者:
Blakely CM;Watkins TBK;Wu W;Gini B;Chabon JJ;McCoach CE;McGranahan N;Wilson GA;Birkbak NJ;Olivas VR;Rotow J;Maynard A;Wang V;Gubens MA;Banks KC;Lanman RB;Caulin AF;St John J;Cordero AR;Giannikopoulos P;Simmons AD;Mack PC;Gandara DR;Husain H;Doebele RC;Riess JW;Diehn M;Swanton C;Bivona TG
通讯作者:
Bivona TG
影响因子:
5.3
作者:
Ciuleanu, T.;Tsai, C. -M.;Thatcher, N.
通讯作者:
Thatcher, N.
影响因子:
11.2
作者:
Arasada RR;Amann JM;Rahman MA;Huppert SS;Carbone DP
通讯作者:
Carbone DP
影响因子:
1.1
作者:
Bartholomew C;Eastlake L;Dunn P;Yiannakis D
通讯作者:
Yiannakis D
影响因子:
3.7
作者:
Benlloch, Susana;Luisa Botero, Maria;Taron, Miquel
通讯作者:
Taron, Miquel